These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30848187)

  • 1. Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives.
    Sarafidis PA; Memmos E; Alexandrou ME; Papagianni A
    Curr Pharm Des; 2018; 24(46):5528-5536. PubMed ID: 30848187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E; White WB; Bakris G
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy.
    Goenka L; Padmanaban R; George M
    Curr Clin Pharmacol; 2019; 14(2):78-83. PubMed ID: 30444201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
    Dojki FK; Bakris G
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):368-374. PubMed ID: 28771453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials.
    Alexandrou ME; Papagianni A; Tsapas A; Loutradis C; Boutou A; Piperidou A; Papadopoulou D; Ruilope L; Bakris G; Sarafidis P
    J Hypertens; 2019 Dec; 37(12):2307-2324. PubMed ID: 31688290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.
    Rico-Mesa JS; White A; Ahmadian-Tehrani A; Anderson AS
    Curr Cardiol Rep; 2020 Sep; 22(11):140. PubMed ID: 32910349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
    Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA
    Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finerenone in diabetic kidney disease: A systematic review and critical appraisal.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Oct; 16(10):102638. PubMed ID: 36223666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA; Gariani K; Martin PY
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
    Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
    Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
    Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid Receptor Antagonists-Use in Chronic Kidney Disease.
    Baran W; Krzemińska J; Szlagor M; Wronka M; Młynarska E; Franczyk B; Rysz J
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.
    Cohen S; Sternlicht H; Bakris GL
    Curr Diab Rep; 2022 May; 22(5):213-218. PubMed ID: 35441935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S; López-Mesa M; Gómez-Fernández P
    Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 33358451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.
    Ortiz A; Ferro CJ; Balafa O; Burnier M; Ekart R; Halimi JM; Kreutz R; Mark PB; Persu A; Rossignol P; Ruilope LM; Schmieder RE; Valdivielso JM; Del Vecchio L; Zoccali C; Mallamaci F; Sarafidis P;
    Nephrol Dial Transplant; 2023 Jan; 38(1):10-25. PubMed ID: 33944938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Finerenone in the Management of Diabetic Nephropathy.
    Veneti S; Tziomalos K
    Diabetes Ther; 2021 Jul; 12(7):1791-1797. PubMed ID: 34050896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of mineralocorticoid receptor antagonists in kidney diseases.
    Patel V; Joharapurkar A; Jain M
    Drug Dev Res; 2021 May; 82(3):341-363. PubMed ID: 33179798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonsteroidal antagonists of the mineralocorticoid receptor.
    Kolkhof P; Nowack C; Eitner F
    Curr Opin Nephrol Hypertens; 2015 Sep; 24(5):417-24. PubMed ID: 26083526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.